SM Energy Company (NYSE:SM) Q4 2025 Earnings call February 26, 2026 10:00 AM ET Speaker7Good morning, and welcome to the SM Energy fourth quarter and full year 2025 financial and operating results and 2026 outlook live session. At this time, all participants will be in a listen-only mode. A question and answer session will follow the formal presentation. Please note, today's event is being recorded. I would now like to turn the call over to Pat Lytle, SM Energy Senior Vice President, Finance. Please go ahea ...

塞舌尔维多利亚, Feb. 26, 2026 (GLOBE NEWSWIRE) -- 全球最大的全景交易所 (UEX) Bitget 今日宣布与 Arkis 达成合作。Arkis 是一家机构级数字资产主经纪商，在中心化和去中心化交易平台提供统一保证金和信贷服务。 此次合作在 Arkis 的主经纪框架内为 Bitget 引入直接市场接入 (DMA)，使机构能够通过单一的、基于投资组合的保证金模型来融资头寸，同时在 Bitget 上进行交易。 通过本次整合，机构客户可以使用熟悉的子账户结构和基于 API 的工作流程在 Bitget 上执行交易，同时可基于覆盖 Bitget 及其他支持平台的统一投资组合保证金进行融资。 该架构用投资组合层面的净额抵销取代了孤立的保证金要求，使交易公司能够更有效地配置资本，并减少在活跃策略中的资产负债表摩擦。 “机构希望将资本部署到最能发挥作用的地方，而无需在平台间管理分散的保证金，”Bitget 首席执行官 Gracy Chen 表示。 “与 Arkis 的整合为机构交易者提供了一种更实用的方式来访问 Bitget，同时在投资组合层面管理风险和融资。 这种架构契合专业交易台的实际 ...

Shifted from cyclical Bitcoin mining CapEx to contracted infrastructure cash flow via the ABC carve-out and River Bend development. Adopted a 'power-first' development strategy, viewing electrons as strategic assets rather than commodities to control the foundational layer of AI infrastructure. Rebuilt the company around capital efficiency and durable cash flow, focusing on compounding assets like power control and scalable campuses. Prioritized institutional credibility, increasing institutional ow ...

Company Presentation February 2026 Forward-Looking Statements All statements, except for statements of historical fact, made within regarding activities, events or developments the Company expects, believes or anticipates will or may occur in the future, such as those regarding future well costs, expected asset sales, well productivity, future liquidity and financial resilience, anticipated exports and related financial impact, NGL market supply and demand, future commodity fundamentals and pricing, future ...

He also detailed the intended use of proceeds: the company plans to repay the term loan used to fund the cash portion of the NuVista acquisition, repay its 2028 notes, and then apply remaining proceeds to the credit facility and commercial paper balance. After those repayments, the company expects its remaining long-term debt to have no maturities before 2030.McCracken said Ovintiv expects the Anadarko sale to close early in the second quarter. After closing, he expects net debt to be roughly $3.6 billion, ...

Ovintiv (NYSE:OVV) Q4 2025 Earnings call February 24, 2026 10:00 AM ET Company ParticipantsBrendan McCracken - President and CEOCorey Code - CFOGreg Givens - EVP and COOGreg Pardy - Managing Director and Head of Global Energy ResearchJason Verhaest - Director of Investor RelationsJosh Silverstein - Managing DirectorKevin MacCurdy - Managing DirectorLloyd Byrne - Managing Director, Equity ResearchNeil Mehta - Head of Americas Natural Resources Equity ResearchPhillip Jungwirth - Managing DirectorNone - Compan ...

Cannara Biotech Update Summary Company Overview - **Company**: Cannara Biotech (OTCPK: LOVF.F) - **Industry**: Cannabis - **Focus**: Canadian cannabis market with a strategy centered on operational efficiency and brand strength Key Points and Arguments Business Model and Strategy - Cannara operates as a second mover in the cannabis industry, focusing on sustainable margins and operational efficiency rather than rapid expansion [3][4] - The company has three flagship brands: Nugz, Tribal, and Orchid, which cover multiple categories and price points while maintaining quality [4][9] - Cannara has built a disciplined operating model that emphasizes market discipline, low-cost production, and a consumer-first approach [6][7] Production Capacity and Facilities - Cannara currently operates two facilities in Quebec with an annual production capacity of approximately 50,000 kilograms, with plans to expand to 100,000 kilograms [5][19] - The Valleyfield post-processing facility is under construction and is expected to unlock additional capacity by the end of fiscal 2026 [6][8] - Incremental capacity growth is planned through activating existing grow rooms rather than building new facilities, ensuring capital efficiency [21][22] Financial Performance - In fiscal 2025, Cannara reported gross revenues of CAD 150.053 million and net revenues of CAD 108 million, with a gross margin of 41% [15] - The company achieved an 86% increase in Adjusted EBITDA, totaling CAD 28.1 million at a 26% margin [15] - For Q1 2026, net revenues were CAD 30.1 million, reflecting a 20% year-over-year growth, with a gross margin of 45% and an Adjusted EBITDA of CAD 8.8 million at a 29% margin [16] Market Position and Share - Cannara's national retail market share increased from 2.9% in fiscal 2024 to 4.1% in Q1 2026, with significant gains in Quebec where it holds a mid-teen market share [10][11] - The company is positioned to capture market share from both smaller and larger competitors, particularly those distracted by international opportunities [43] Capital and Investment Strategy - Cannara achieved OTCQX qualification and is seeking conditional approval for listing on the TSX, which would enhance visibility and liquidity [8][14] - A recent CAD 6.3 million private placement was completed at a 16% premium to the share price, strengthening the balance sheet for future growth [8][14] - The company plans to allocate approximately CAD 30 million for capital expenditures over the next few years to support expansion [45] Risk Management and Inventory Control - Cannara employs a disciplined approach to inventory management, adjusting production based on market demand to avoid overproduction [48][49] - The company is focused on maintaining gross margins between 40% and 45%, with strategies in place to remain competitive on pricing without sacrificing quality [37][38] Future Outlook - Cannara's growth strategy is centered on the Canadian market, with plans to double its market share and expand its product offerings [30][34] - The company is exploring potential international opportunities but remains committed to its core Canadian operations [35][36] Leadership and Governance - The leadership team, including CEO Zohar Krivorot, emphasizes disciplined execution and long-term value creation [24][25] - The board includes members with extensive experience in public company governance and regulatory compliance, providing a competitive advantage [25] Additional Important Insights - Cannara's brands have received recognition in industry awards, validating their market position and consumer appeal [7] - The company is focused on genetic innovation to enhance product offerings and maintain competitive margins [39][41] - Cannara's operational model is designed to be replicable, with potential for future expansion into international markets as conditions allow [62]

Core Insights - Dolby Laboratories, Inc. is recognized for its innovative sound technologies and competes with companies like NETGEAR, Inc., Morningstar, Inc., Copart, Inc., and MSC Industrial Direct Co., Inc. in financial performance and capital efficiency [1] Financial Performance - Dolby has a Return on Invested Capital (ROIC) of 8.76% and a Weighted Average Cost of Capital (WACC) of 7.63%, resulting in a ROIC to WACC ratio of 1.15, indicating efficient capital utilization [2][6] - Copart, Inc. leads the group with a ROIC to WACC ratio of 1.65, showcasing superior efficiency in generating returns over its cost of capital [3][6] - Morningstar, Inc. and MSC Industrial Direct Co., Inc. have ROIC to WACC ratios of 1.37 and 1.61, respectively, highlighting their strong capital efficiency [4] - NETGEAR, Inc. has a negative ROIC to WACC ratio of -0.69, indicating inefficiency in generating returns above its cost of capital [5][6]

Stablecoins won the utility war, but they are losing the "capital efficiency" war. Currently, $270B in "Lazy Money" gifts centralised issuers $9.7B in annual interest while users carry the risk.We’re entering the Productivity Meta - reclaiming the float for DAO treasuries, DEX liquidity, and neobank balances. From vertical solutions like HyENA to horizontal "Yield-as-a-Service" layers like @solomon_labs, new infrastructure is emerging to enable native yield without the friction of wrapping or changing ticke ...

Core Insights - Arrowhead Pharmaceuticals focuses on developing medicines for intractable diseases by silencing the genes that cause them, operating in a competitive biopharmaceutical industry alongside peers like Alnylam Pharmaceuticals, Amicus Therapeutics, ACADIA Pharmaceuticals, and Axsome Therapeutics [1] Financial Metrics Comparison - Arrowhead Pharmaceuticals has a Return on Invested Capital (ROIC) of 20.84%, significantly higher than its Weighted Average Cost of Capital (WACC) of 9.86%, resulting in a ROIC to WACC ratio of 2.11, indicating efficient capital utilization and potential for growth [2] - Alnylam Pharmaceuticals shows a negative ROIC of -10.44% against a WACC of 5.30%, leading to a ROIC to WACC ratio of -1.97, highlighting inefficiencies in capital utilization [3] - Amicus Therapeutics also reports a negative ROIC of -13.65% with a WACC of 6.20%, resulting in a ROIC to WACC ratio of -2.20, indicating challenges in generating returns above its cost of capital [3] - ACADIA Pharmaceuticals stands out with a ROIC of 23.32% and a WACC of 6.74%, yielding a ROIC to WACC ratio of 3.46, suggesting strong capital efficiency and growth potential [4] - Axsome Therapeutics has a notably negative ROIC of -55.37%, far below its WACC of 5.53%, resulting in a ROIC to WACC ratio of -10.02, indicating significant challenges in capital utilization [5][6]